Literature DB >> 6771658

Titration of human brain monoamine oxidase -A and -B by clorgyline and L-deprenil.

C J Fowler, L Oreland, J Marcusson, B Winblad.   

Abstract

The interaction of clorgyline and L-deprenil with the -A and -B forms of human brain monoamine oxidase (MAO) has been studied. Both compounds inhibit cerebrocortical MAO in a manner consistent with a 'suicide' inactivation of the enzyme. The interaction of clorgyline with the -A form of the enzyme appears to take place almost entirely at specific binding sites, and the conditions required for this inhibitor to 'titrate' the concentrations of MAO-A have been elucidated. L-Deprenil has also been used to titrate the concentration of the -B form of MAO in cerebrocortical homogenates, but there is a considerable degree of non-specific binding of this compound. The two inhibitors have been used to titrate the concentrations of the two enzyme forms in frontal cortex homogenates from different age groups. There was a significantly higher MAO-B activity for the age range 73--95 years than for the age range 2--63 years. No significant differences between the two age groups were found for MAO-A. The activity of MAO-A in the samples correlated very well with the concentration of this enzyme form. Titration of the B-form of the enzyme with L-deprenil indicated an increased enzyme concentration with age, although other factors, such as the non-specific binding of this compound, could contribute to this effect.

Entities:  

Mesh:

Substances:

Year:  1980        PMID: 6771658     DOI: 10.1007/bf00569406

Source DB:  PubMed          Journal:  Naunyn Schmiedebergs Arch Pharmacol        ISSN: 0028-1298            Impact factor:   3.000


  33 in total

1.  The development of monoamine oxidase in rat liver and brain.

Authors:  T J Mantle; N J Garrett; K F Tipton
Journal:  FEBS Lett       Date:  1976-04-15       Impact factor: 4.124

2.  Quantitative aspects on mitochondrial monoamine oxidase in human platelets.

Authors:  A Wiberg; L Oreland
Journal:  Med Biol       Date:  1976-04

3.  A modification of the Lowry procedure to simplify protein determination in membrane and lipoprotein samples.

Authors:  M A Markwell; S M Haas; L L Bieber; N E Tolbert
Journal:  Anal Biochem       Date:  1978-06-15       Impact factor: 3.365

Review 4.  Developmental characteristics of monamine oxidase.

Authors:  D Gripois
Journal:  Comp Biochem Physiol C       Date:  1975-08-01

5.  Letter: Brain-levels of monoamine oxidase in depression.

Authors:  C F Gottfries; L Oreland; A Wiberg; B Winblad
Journal:  Lancet       Date:  1974-08-10       Impact factor: 79.321

6.  The mechanism of action of the monoamine oxidase inhibitor pargyline.

Authors:  L Oreland; H Kinemuchi; B Y Yoo
Journal:  Life Sci       Date:  1973-12-01       Impact factor: 5.037

7.  Some puzzling pharmacological effects of monoamine oxidase inhibitors.

Authors:  J Knoll; K Magyar
Journal:  Adv Biochem Psychopharmacol       Date:  1972

8.  Relation of sex and aging to monoamine oxidase activity of human brain, plasma, and platelets.

Authors:  D S Robinson; J M Davis; A Nies; C L Ravaris; D Sylwester
Journal:  Arch Gen Psychiatry       Date:  1971-06

9.  Monoamine metabolism in human brain.

Authors:  D S Robinson; T L Sourkes; A Nies; L S Harris; S Spector; D L Bartlett; I S Kaye
Journal:  Arch Gen Psychiatry       Date:  1977-01

10.  Evidence for a single catalytic binding site on human brain type B monoamine oxidase.

Authors:  J A Roth
Journal:  J Neurochem       Date:  1976-11       Impact factor: 5.372

View more
  16 in total

1.  Expression of monoamine oxidase B activity in astrocytes of senile plaques.

Authors:  S Nakamura; T Kawamata; I Akiguchi; M Kameyama; N Nakamura; H Kimura
Journal:  Acta Neuropathol       Date:  1990       Impact factor: 17.088

2.  The deamination of dopamine by human brain monoamine oxidase. Specificity for the two enzyme forms in seven brain regions.

Authors:  A M O'Carroll; C J Fowler; J P Phillips; I Tobbia; K F Tipton
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1983-04       Impact factor: 3.000

3.  Inhibition of MAO-B by (-)-deprenyl alters dopamine metabolism in the macaque (Macaca facicularis) brain.

Authors:  I A Paterson; B A Davis; D A Durden; A V Juorio; P H Yu; G Ivy; W Milgram; A Mendonca; P Wu; A A Boulton
Journal:  Neurochem Res       Date:  1995-12       Impact factor: 3.996

4.  Localization of monoamine oxidase B in human brain by autoradiographical use of 11C-labelled L-deprenyl.

Authors:  S S Jossan; R d'Argy; P G Gillberg; S M Aquilonius; B Långström; C Halldin; P Bjurling; C G Stålnacke; J Fowler; R MacGregor
Journal:  J Neural Transm       Date:  1989       Impact factor: 3.575

5.  The effect of age on the activity and molecular properties of human brain monoamine oxidase.

Authors:  C J Fowler; A Wiberg; L Oreland; J Marcusson; B Winblad
Journal:  J Neural Transm       Date:  1980       Impact factor: 3.575

Review 6.  Selegiline. A review of its pharmacology, symptomatic benefits and protective potential in Parkinson's disease.

Authors:  P Chrisp; G J Mammen; E M Sorkin
Journal:  Drugs Aging       Date:  1991-05       Impact factor: 3.923

7.  Predominance of oxidative deamination in the metabolism of exogenous noradrenaline by the normal and chemically denervated human uterine artery.

Authors:  D Branco; M Caramona; F Martel; J A de Almeida; W Osswald
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1992-09       Impact factor: 3.000

8.  Monoamine oxidase-A and -B activities in the brain stem of schizophrenics and non-schizophrenic psychotics.

Authors:  C J Fowler; A Carlsson; B Winblad
Journal:  J Neural Transm       Date:  1981       Impact factor: 3.575

9.  Muscarinic receptor compensation in hippocampus of Alzheimer patients.

Authors:  A Nordberg; C Larsson; R Adolfsson; I Alafuzoff; B Winblad
Journal:  J Neural Transm       Date:  1983       Impact factor: 3.575

10.  The binding of [3H]-5-hydroxytryptamine to homogenates of human brain.

Authors:  E Dehlin; J Marcusson; C J Fowler; B Winblad
Journal:  J Neural Transm       Date:  1982       Impact factor: 3.575

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.